Atrial Natriuretic Factor

• 

  Subject Areas on Research

  • A requirement for the rac1 GTPase in the signal transduction pathway leading to cardiac myocyte hypertrophy. 
  • ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. 
  • Acute decompensated heart failure: update on new and emerging evidence and directions for future research. 
  • Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators. 
  • Adverse effects of constitutively active alpha(1B)-adrenergic receptors after pressure overload in mouse hearts. 
  • Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. 
  • Alterations in serum sodium in relation to atrial natriuretic factor and other neuroendocrine variables in experimental pacing-induced heart failure. 
  • Analysis of BAG3 plasma concentrations in patients with acutely decompensated heart failure. 
  • Angiotensinogen gene null-mutant mice lack homeostatic regulation of glomerular filtration and tubular reabsorption. 
  • Atrial natriuretic factor-specific antibody as a tool for physiological studies. Evidence for role of atrial natriuretic factor in aldosterone and renal electrolyte regulation. 
  • Atrial natriuretic factor: pharmacokinetics and cyclic GMP response in relation to biologic effects in severe heart failure. 
  • Atrial natriuretic hormone, vessel dilator, long acting natriuretic hormone, and kaliuretic hormone decrease circulating prolactin concentrations. 
  • Atrial natriuretic hormone, vessel dilator, long-acting natriuretic hormone, and kaliuretic hormone decrease the circulating concentrations of CRH, corticotropin, and cortisol. 
  • Atrial natriuretic hormone, vessel dilator, long-acting natriuretic hormone, and kaliuretic hormone decrease the circulating concentrations of total and tree T4 and free T3 with reciprocal increase in TSH. 
  • Atrial natriuretic peptide increases adrenomedullin in the circulation of healthy humans. 
  • Atrial natriuretic peptide increases urodilatin in the circulation. 
  • Atrial natriuretic peptide-induced changes in renal prostacyclin production in ureteral obstruction. 
  • Atrial natriuretic peptides and cyclic guanosine monophosphate metabolism. 
  • Atrial natriuretic peptides increase calcitonin gene-related peptide within human circulation. 
  • Atrial natriuretic peptides negatively and positively modulate circulating endothelin in humans. 
  • Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. 
  • Autocrine and paracrine effects of atrial natriuretic peptide gene transfer on vascular smooth muscle and endothelial cellular growth. 
  • Cardiac gene expression profiling provides evidence for cytokinopathy as a molecular mechanism in Chagas' disease cardiomyopathy. 
  • Cerebrospinal fluid atrial natriuretic factor in intracranial disease. 
  • Chronic elevation of calmodulin in the ventricles of transgenic mice increases the autonomous activity of calmodulin-dependent protein kinase II, which regulates atrial natriuretic factor gene expression. 
  • Combined treatment with vessel dilator and kaliuretic hormone in persons with congestive heart failure. 
  • Contributions of neuroendocrine and local autocrine-paracrine mechanisms to the pathophysiology and pharmacology of congestive heart failure. 
  • Cross-sectional relations of multiple biomarkers representing distinct biological pathways to plasma markers of collagen metabolism in the community. 
  • Detection and characterization of methionine oxidation in peptides by collision-induced dissociation and electron capture dissociation. 
  • Disposition of vessel dilator and long-acting natriuretic peptide in healthy humans after a one-hour infusion. 
  • Divergent pathways mediate the induction of ANF transgenes in neonatal and hypertrophic ventricular myocardium. 
  • Does a hypertonic saline load predict fluid retention in pacing induced heart failure? 
  • Dual natriuretic peptide system in experimental heart failure. 
  • Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. 
  • Effects of atrial natriuretic peptide on the coronary arterial vasculature in humans. 
  • Effects of kaliuretic peptide on sodium and water excretion in persons with congestive heart failure. 
  • Four cardiac hormones increase circulating concentrations of luteinizing hormone and testosterone. 
  • Gender-specific patterns of left ventricular and myocyte remodeling following myocardial infarction in mice deficient in the angiotensin II type 1a receptor. 
  • Glomerular atrial natriuretic factor receptors in primary glomerulopathies: studies on human renal biopsies. 
  • Higher aldosterone and lower N-terminal proatrial natriuretic peptide as biomarkers of salt sensitivity in the community. 
  • How does intermittent pacing modify the response to rapid ventricular pacing in experimental heart failure? 
  • Hybrid transgenic mice reveal in vivo specificity of G protein-coupled receptor kinases in the heart. 
  • Inhibition of betaARK1 restores impaired biochemical beta-adrenergic receptor responsiveness but does not rescue CREB(A133) induced cardiomyopathy. 
  • Intact negative feedback of four cardiac hormones in congestive heart failure. 
  • Interaction of atrial natriuretic polypeptide and angiotensin II on protooncogene expression and vascular cell growth. 
  • Kaliuretic peptide and long acting natriuretic peptide as well as atrial natriuretic factor inhibit aldosterone secretion. 
  • Lipopolysaccharide induces oxidative cardiac mitochondrial damage and biogenesis. 
  • Localization of specific binding sites for atrial natriuretic factor in peripheral tissues of the guinea pig, rat, and human. 
  • Localization of specific binding sites for atrial natriuretic factor in the central nervous system of rat, guinea pig, cat and human. 
  • Long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance the urinary excretion rate of beta2-microglobulin. 
  • Long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance urinary excretion rate of albumin, total protein, and beta(2)-microglobulin in patients with congestive heart failure. 
  • Marked enhancement in myocardial function resulting from overexpression of a human beta-adrenergic receptor gene. 
  • Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. 
  • Mid-regional pro-atrial natriuretic peptide to predict clinical course in heart failure patients undergoing cardiac resynchronization therapy. 
  • Modulation of gene expression in neonatal rat cardiomyocytes by surface modification of polylactide-co-glycolide substrates. 
  • Multi-marker strategy of natriuretic peptide with either conventional or high-sensitivity troponin-T for acute coronary syndrome diagnosis in emergency department patients with chest pain: from the "Rule Out Myocardial Infarction using Computer Assisted Tomography" (ROMICAT) trial. 
  • Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. 
  • Myocardial expression of a constitutively active alpha 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. 
  • N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. 
  • Natriuretic peptides in heart failure and acute coronary syndrome. 
  • Natriuretic peptides in heart failure with preserved ejection fraction. 
  • Natriuretic peptides in the diagnosis and management of heart failure. 
  • Negative feedback of atrial natriuretic peptides. 
  • Nomenclature for atrial peptides. 
  • Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. 
  • Obese patients have lower B-type and atrial natriuretic peptide levels compared with nonobese. 
  • Pathophysiological role of changing atrial size and pressure in modulation of atrial natriuretic factor during evolving experimental heart failure. 
  • Pharmacokinetics, hemodynamic, renal, and neurohormonal effects of atrial natriuretic factor in experimental heart failure. 
  • Physiological effects of synthetic atrial natriuretic factor in normal conscious dogs. 
  • Plasma and cardiac tissue atrial and brain natriuretic peptides in experimental heart failure. 
  • Plasma atrial natriuretic factor during chronic thoracic inferior vena caval constriction. 
  • Progressive cardiac dysfunction and fibrosis in the cardiomyopathic hamster and effects of growth hormone and angiotensin-converting enzyme inhibition. 
  • Psychosocial correlates of atrial natriuretic peptide: a marker of vascular health. 
  • Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. 
  • Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure. 
  • Recent advances in pancreatic endocrine and exocrine secretion. 
  • Receptor binding sites for atrial natriuretic factor are expressed by brown adipose tissue. 
  • Relation of atrial natriuretic factor to vasoconstrictor hormones and regional blood flow in congestive heart failure. 
  • Renal and circulatory mechanisms in congestive heart failure. 
  • Report of the Joint Nomenclature and Standardization Committee of the International Society of Hypertension, American Heart Association and the World Health Organization. 
  • Response of atrial natriuretic factor to acute and chronic increases of atrial pressures in experimental heart failure in dogs. Role of changes in heart rate, atrial dimension, and cardiac tissue concentration. 
  • Response of atrial natriuretic factor to postural change in patients with heart failure versus subjects with normal hemodynamics. 
  • Responsiveness of atrial natriuretic factor to reduction in right atrial pressure in patients with chronic congestive heart failure. 
  • Role of guanylate cyclase modulators in decompensated heart failure. 
  • Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. 
  • Sequential changes in atrial pressures, dimensions, and plasma atrial natriuretic factor concentrations during volume loading in hemodynamically normal human subjects. 
  • Specific binding sites for atrial natriuretic factor in the human kidney. 
  • Stimulation of aquaporin-mediated fluid transport by cyclic GMP in human retinal pigment epithelium in vitro. 
  • Structure and function of the beta 2-adrenergic receptor--homology with rhodopsin. 
  • Surfing the biomarker tsunami at JACC: heart failure. 
  • Synthetic atrial natriuretic factor decreases renal tubular phosphate reabsorption in rats. 
  • Targeted developmental overexpression of calmodulin induces proliferative and hypertrophic growth of cardiomyocytes in transgenic mice. 
  • Targeted overexpression of phospholamban to mouse atrium depresses Ca2+ transport and contractility. 
  • Targeting heart failure therapeutics: a historical perspective. 
  • Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. 
  • The international standard for atrial natriuretic factor. Calibration by an international collaborative study. 
  • The responses of atrial natriuretic factor concentrations to acute volume changes in conscious rats. 
  • Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans. 
  • Transgenic mice with cardiac overexpression of alpha1B-adrenergic receptors. In vivo alpha1-adrenergic receptor-mediated regulation of beta-adrenergic signaling. 
  • Vasodilators in the treatment of acute heart failure: what we know, what we don't. 
  • Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure. 
  • Vessel dilator, long acting natriuretic peptide, and kaliuretic peptide increase circulating prostaglandin E2. 
• 

  Keywords of People

  • Hogan, Brigid L. M., George Barth Geller Professor, Cell Biology
  • Milano, Carmelo Alessio, Professor of Surgery, Surgery, Cardiovascular and Thoracic Surgery